vimarsana.com

Page 268 - இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase-3 Trials Show Covaxin 93 4 Per Cent Effective Against Severe COVID-19 But Supply Marred By Delay In Manufacturing

Phase-3 Trials Show Covaxin 93 4 Per Cent Effective Against Severe COVID-19 But Supply Marred By Delay In Manufacturing
swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.

Ocugen s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77 8% Protection against Overall Disease

Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Home / Top News / Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19 Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events MALVERN, Pa., and HYDERABAD, India, July 02, 2021 (GLOBE NEWSWIRE)

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.